5 окт. 2023 г. · By modulating the TYK2 pathway, this development candidate has the potential to treat a wide range of autoimmune and autoinflammatory diseases, ...

ATMW-DC is a novel, oral, allosteric inhibitor of TYK2, with potency and selectivity in biochemical and cellular assays.

2 апр. 2024 г. · Atomwise plans to file an IND application this year for its lead candidate, a novel allosteric TYK2 inhibitor with first-in-class and best ...

2 окт. 2023 г. · For its TYK2 drug, Atomwise hopes to file an IND in the second half of 2024. Heifets said he believes the drug could show better efficacy in ...

6 окт. 2023 г. · By modulating the TYK2 pathway, this compound could be used to treat various autoimmune and autoinflammatory diseases. Atomwise plans to submit ...

2 апр. 2024 г. · Atomwise's TYK2 inhibitor serves as an example of AI exploring new chemical space. “For TYK2, we think it's a good example of what happens ...

19 июн. 2024 г. · ... TYK2 developed using Atomwise's drug discovery platform Atomnet, for the potential treatment of psoriatic inflammation. TYK2, integral to IL ...

Deucravacitinib, which is approved for the treatment of moderate to severe plaque psoriasis in adults in the United States and several other countries,

4 окт. 2023 г. · The orally bioavailable and allosteric TYK2 inhibitor has the potential to treat a wide range of autoimmune and autoinflammatory diseases, ...

2 окт. 2024 г. · In an interview a year ago, Heifets told Endpoints Atomwise aimed to file an IND for its lead drug, a TYK2 inhibitor, in the second half of 2024 ...